Identification of Biomarkers for Early Detection of Environmentally Induced Mitochondrial Dysfunction (R01) | Apply Online

FAQs: NIH FOA RFA-ES-11-007 (Early Biomarkers of Environmentally Induced Mitochondrial Dysfunction)

What is the purpose of this funding opportunity (RFA-ES-11-007)?

This NIH Funding Opportunity Announcement (FOA), RFA-ES-11-007, supports research to identify and validate early biomarkers of mitochondrial dysfunction caused by environmental exposures. The emphasis is on practical, measurable biological indicators that can signal the start of harmful mitochondrial disruption before obvious disease, tissue injury, or major pathology appears.

What is meant by "early biomarkers" in this FOA?

In this program, early biomarkers are measurable biological signals that change when environmental stressors or toxicants begin to interfere with normal mitochondrial function. The intent is to find markers that act as early warning signs, rather than endpoints that only show up after substantial damage has already occurred.

Why does the FOA focus on mitochondria in relation to environmental exposures?

The FOA is motivated by the role of mitochondria in core biological processes, including energy production, redox balance, apoptosis signaling, and metabolic regulation. Because mitochondria sit at the center of these processes, mitochondrial toxicity can serve as a common pathway through which many different environmental agents contribute to disease.

What kinds of studies does the FOA prioritize to develop these biomarkers?

The FOA emphasizes using animal models and other experimental systems to develop, test, and validate candidate biomarkers. The longer-term goal is to create a strong scientific foundation for applying the best-performing markers in human population studies that link exposure to later health outcomes.

Does the FOA emphasize translation to human studies?

Yes. While the work is expected to be grounded in animal and experimental models, the program is designed to build a credible bridge to human population research. That includes preparing biomarkers that can eventually be used in epidemiologic studies where real-world complexity and limited tissue access make interpretation more challenging.

Why does the FOA highlight tissue specificity in mitochondrial responses?

The FOA notes that mitochondrial biology is not uniform across the body. The same environmental exposure can produce different mitochondrial responses depending on the tissue, developmental stage, diet and nutrient composition, and underlying genetics. This complexity is a major reason the FOA calls for biomarker development that avoids simplistic, one-size-fits-all endpoints.

What is the "target tissue vs surrogate tissue" issue mentioned in the FOA?

In many human studies, researchers cannot easily sample the most affected organs (such as brain, heart, or specific liver regions). Instead, they may rely on accessible tissues like blood cells or buccal cells. The FOA encourages research that clarifies how mitochondrial effects in true target tissues relate to signals measured in surrogate tissues, and whether surrogate measures can reliably track biologically meaningful early dysfunction.

What kinds of surrogate tissues are mentioned as examples?

The FOA provides examples of accessible surrogate samples commonly used in human research, such as blood cells and buccal cells, as well as other minimally invasive tissues.

What does the FOA mean by distinguishing "adaptive" versus "adverse" mitochondrial changes?

Mitochondrial endpoints can shift temporarily as a short-term adaptive response to stress, or persist in a way that reflects accumulating damage and increased disease risk. The FOA seeks studies that can separate adaptive changes from adverse dysfunction and identify endpoints that indicate early functional disruption before overt pathology or major phenotypic changes occur.

Is the FOA looking for descriptive measurements or mechanistic understanding?

The FOA is not aimed at collecting descriptive readouts alone. It encourages research that improves mechanistic understanding of how mitochondrial toxicants act, which pathways are perturbed, and which measurements best capture those perturbations in a robust and interpretable way that can support later translation to epidemiology and exposure science.

What role do genetics, diet, and developmental stage play in the FOA's research vision?

The FOA explicitly highlights that mitochondrial responses to environmental exposures can vary with genetics, diet and nutrient composition, and developmental timing. It supports biomarker development approaches that account for these modifiers so that candidate markers are more interpretable and more likely to translate to diverse human populations.

What overall gap is this FOA trying to address for human translation?

The FOA targets several translation gaps, including limited access to affected organs in humans, uncertainty about whether surrogate tissues reflect target-tissue dysfunction, and difficulty interpreting whether mitochondrial changes represent adaptation or early harmful disruption. The aim is to produce robust, reproducible markers with a clear interpretation that can later be applied in population studies.

What grant mechanism is used for this opportunity?

This opportunity uses the NIH R01 research project grant mechanism.

What is the CFDA number and general area of this FOA?

The CFDA number is 93.113, and the FOA is in the environmental health area.

Is this discretionary funding, and is cost sharing required?

It is categorized as discretionary funding, and it does not require cost sharing or matching.

When was the FOA posted, and what were the closing dates?

The FOA was posted on November 30, 2010. The original and current closing date listed is February 3, 2011.

Is this FOA still active?

No. The FOA was archived on March 6, 2011.

How much funding was estimated to be available under this FOA?

The estimated total funding available was $2,500,000.

Who is eligible to apply based on the FOA description?

Eligibility is broad and includes public and private institutions of higher education, nonprofits (including but not limited to 501(c)(3) organizations), for-profit organizations (including entities other than small businesses), small businesses, state and local governments, tribal governments and tribal organizations, independent school districts, public housing authorities/Indian housing authorities, and other categories listed in the announcement.

Does the FOA explicitly include minority-serving institutions and community-based organizations?

Yes. The eligibility section explicitly notes inclusion of Alaska Native and Native Hawaiian Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), as well as faith-based or community-based organizations.

Are U.S. territories, federal agencies, or foreign entities eligible?

Yes. The FOA explicitly includes U.S. territories or possessions, regional organizations, eligible federal agencies, and non-U.S. (foreign) entities.

What is the practical takeaway of this FOA for prospective applicants?

The FOA was designed to fund rigorous, model-driven work that identifies early, interpretable, and translatable biomarkers of mitochondrial dysfunction tied to environmental exposures. It encourages applicants to address tissue specificity, developmental timing, diet and genetic modifiers, surrogate-versus-target tissue relationships, and the adaptive-versus-adverse nature of mitochondrial changes to support eventual use of validated markers in human population studies.